

1 **Cellular and Humoral Immunity to Ebola Zaire Glycoprotein and Viral Vector Proteins**  
2 **Following Immunization with Recombinant Vesicular Stomatitis Virus-Based Ebola**  
3 **Vaccine (rVSV $\Delta$ G-EBOV-GP)**

4 Vanessa Raabe<sup>1,2\*</sup>, Lilin Lai<sup>1</sup>, Juliet Morales<sup>1,3</sup>, Yongxian Xu<sup>1</sup>, Nadine Rouphael<sup>1</sup>, Richard T.  
5 Davey<sup>4</sup>, Mark J. Mulligan<sup>1,2</sup>

6 \* Corresponding author

7 **Affiliations:**

8 1 Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of  
9 Medicine, School of Medicine, Emory University, 500 Irvin Court, Suite 200, Decatur, GA,  
10 30030, USA

11 2 Present address: Division of Infectious Diseases & Immunology and NYU Langone Vaccine  
12 Center, Department of Medicine, New York University Grossman School of Medicine,  
13 Alexandria Center for Life Sciences West Tower, 3rd Floor, New York, NY, 10016, USA

14 3 Present address: Division of Global Disease Epidemiology and Control, Department of  
15 International Health, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street,  
16 Baltimore, MD, 21205, USA

17 4 National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center  
18 Drive, Rm. 4-1479, MSC 1460, Bethesda, MD 20892, USA

19 **Author Email:** Vanessa Raabe: [Vanessa.Raabe@nyulangone.org](mailto:Vanessa.Raabe@nyulangone.org); Yongxian Xu:  
20 [y.xu@emory.edu](mailto:y.xu@emory.edu); Juliet Morales: [jmoral22@jh.edu](mailto:jmoral22@jh.edu); Lilin Lai: [llai@emory.edu](mailto:llai@emory.edu); Nadine  
21 Rouphael: [nroupha@emory.edu](mailto:nroupha@emory.edu); Richard T. Davey: [rdavey@niaid.nih.gov](mailto:rdavey@niaid.nih.gov); Mark J. Mulligan:  
22 [Mark.Mulligan@nyulangone.org](mailto:Mark.Mulligan@nyulangone.org)

23

24 Word Count: 4850

25 Abstract Word Count: 289

26

27 **Abstract**

28 While effective at preventing Zaire ebolavirus (EBOV) disease, cellular immunity to EBOV and  
29 vector-directed immunity elicited by the recombinant vesicular stomatitis virus expressing Ebola  
30 glycoprotein (rVSV $\Delta$ G-EBOV-GP) vaccine remains poorly understood. Sera and peripheral  
31 blood mononuclear cells were collected from 32 participants enrolled in a prospective  
32 multicenter study [ClinicalTrials.gov NCT02788227] before vaccination and up to six months  
33 post-vaccination. IgM and IgG antibodies, IgG-producing memory B cells, and T cell reactivity  
34 to EBOV glycoprotein, vesicular stomatitis virus-Indiana strain (VSV-I) matrix protein, and  
35 VSV-I nucleoprotein were measured using ELISA, ELISpot, and intracellular cytokine staining,  
36 respectively. Eleven participants previously received a different investigational Ebola vaccine.  
37 All participants met positivity criteria for IgG antibodies to, and circulating IgG-producing  
38 memory B cells to, EBOV glycoprotein following rVSV $\Delta$ G-EBOV-GP vaccination. Transient  
39 IgM and IgG antibody responses to VSV-I matrix protein (n=1/32 and n=0/32, respectively) and  
40 nucleoprotein (n=2/32 and n=1/32, respectively) were infrequently detected, as were IgG-  
41 producing memory B cells recognizing VSV-I matrix protein (n=3/31) and nucleoprotein  
42 (n=2/31). CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses to EBOV glycoprotein were present in 15/32 and  
43 19/32 participants at baseline and in 32/32 and 23/32 participants one month post-vaccination,  
44 respectively. CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses to VSV-I matrix protein (n=17/32 and n=16/32,  
45 respectively) and VSV-I nucleoprotein (n=23/32 for both CD4<sup>+</sup> and CD8<sup>+</sup> responses) were  
46 common post-vaccination. T cell responses were predominantly mono-cytokine, except CD8<sup>+</sup>

47 responses to EBOV glycoprotein among heterologous Ebola vaccine-experienced participants  
48 and CD8+ responses to VSV-I nucleoprotein. Overall, rVSV $\Delta$ G-EBOV-GP elicits robust  
49 humoral and memory B cell responses to EBOV glycoprotein in both Ebola vaccine-naïve and  
50 heterologous Ebola vaccine-experienced individuals and can generate vector-directed T cell  
51 immunity. Further research is needed to understand the significance of pre-existing vector-  
52 directed immunity on responses to booster doses of rVSV $\Delta$ G-EBOV-GP and other rVSV-  
53 vectored vaccines.

54

55 **Keywords:** Ebola Vaccine; Vesicular stomatitis-Indiana virus; Recombinant vaccines;  
56 Antibodies; T Cell; B cell

57

58 **Abbreviations:** ChAd3-EBO-Z - replication-defective chimpanzee adenovirus 3 vector vaccine  
59 expressing Zaire ebolavirus glycoprotein; EBOV – Ebola virus; GP – glycoprotein; M – Matrix  
60 protein; MBC – Memory B cell; MVA-BN-Filo - modified vaccinia Ankara virus expression  
61 Zaire ebolavirus glycoprotein and other filovirus antigens; NP – Nucleoprotein; PREPARE - The  
62 Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for  
63 Ebola-Zaire for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for  
64 Ebola Virus Exposure; rVSV- Recombinant vesicular stomatitis virus; rVSV $\Delta$ G-EBOV-GP –  
65 Recombinant vesicular stomatitis virus Ebola vaccine; VSV-I – Vesicular stomatitis virus  
66 Indiana strain

67

68 **Funding:** This work was supported by the National Institute of Allergy and Infectious Diseases  
69 (NIAID), National Institutes of Health (NIH), Department of Health and Human Services [grant

70 number T32AI074492 to V.R, N.R., and M.J.M.] and NIH/NIAID contract number  
71 HHSN272201300018I/HHSN27200021 to Emory University Vaccine and Treatment Evaluation  
72 Unit. The content is solely the responsibility of the authors and does not necessarily represent the  
73 official views of the National Institute of Allergy and Infectious Diseases or the National  
74 Institutes of Health.

75

76 **Competing Interests:** MJM received research contracts from Lilly, Pfizer, and Sanofi, and  
77 serves on advisory boards for Pfizer and Meissa Vaccines. VR received a research contract from  
78 Sanofi. NR received research contracts from Lilly, Pfizer, Merck, Quidel, and Sanofi.

79

## 80 **Introduction**

81 Ebola virus disease is a continuing threat to human health since it was first identified in 1976,  
82 notably causing large-scale outbreaks in West Africa from 2014-2016 involving over 28,000  
83 cases and 11,325 deaths and in the Democratic Republic of Congo from 2018-2020 with over  
84 3400 cases and 2200 deaths [1, 2]. These large-scale epidemics accelerated the development and  
85 testing of Zaire ebolavirus (EBOV) vaccines, leading to European Medicines Agency and the  
86 U.S. Food and Drug Administration approval of a recombinant vesicular stomatitis virus  
87 expressing Ebola glycoprotein (rVSV $\Delta$ G-EBOV-GP) vaccine in 2019 for the prevention of  
88 disease due to Zaire ebolavirus [3, 4]. This vaccine utilizes a replication-competent vesicular  
89 stomatitis virus – Indiana strain (VSV-I) from which the VSV-I glycoprotein (GP) gene has been  
90 removed and replaced by the EBOV GP gene. The efficacy of the rVSV $\Delta$ G-EBOV-GP vaccine  
91 for prevention of disease due to EBOV was estimated from a ring-vaccination study during an  
92 Ebola outbreak to be 97.5% ten days or more post-vaccination and 88.1% at any time post-  
93 vaccination following administration of a single dose over a follow up period of approximately  
94 11 months [5]. Ebola GP antibodies primarily mediate the protection conferred by the rVSV $\Delta$ G-  
95 EBOV-GP vaccine although the vaccine can elicit both CD4+ and CD8+ T cell responses to  
96 EBOV GP [6, 7]. A combination of EBOV GP antibody titers  $\geq$  200 EU/mL plus a minimum 2-  
97 fold rise in EBOV GP antibody titers post-vaccination has been proposed as a vaccine-induced  
98 seroresponse in humans, although a minimum antibody titer necessary to confer protection has  
99 not been established [8]. CD4+ T cells play an important role in vaccine-induced antibody  
100 development, but not in protection at the time of EBOV challenge, while CD8+ T cells may play  
101 a minor role in protection [7, 9].

102

103 Knowledge gaps remain regarding cellular immunity to EBOV GP and vector-induced immunity  
104 elicited by rVSVΔG-EBOV-GP vaccination. Understanding vaccine vector-induced immunity is  
105 important to assess for any unintended, potentially adverse consequences associated with use of  
106 vectored vaccines in the setting of pre-existing vector immunity, such as modification of  
107 vaccine-induced target antigen immunity or the potential to enhance susceptibility to infection,  
108 as was observed among studies of adenovirus type 5 vectored HIV vaccine recipients [10-13],  
109 but also to understand the potential for vector-induced immunity to limit target antigen immune  
110 responses generated by subsequently administered vaccine doses utilizing the same vector.  
111 Human infection with VSV-I is rare and the prevalence of naturally acquired VSV-I antibodies is  
112 generally low with the exceptions of a few, geographically restricted regions [14]. The rVSVΔG-  
113 EBOV-GP vaccine can elicit anti-VSV-I antibodies in non-human primates, although these did  
114 not interfere with protection induced by a subsequently administered and similarly designed  
115 recombinant vesicular stomatitis virus (rVSV) vaccine expressing Lassa virus GP [15]. In  
116 retrospective analysis of a phase I clinical trial, transient, non-neutralizing antibodies directed  
117 against the VSV-I matrix (M) protein and T cell responses against the VSV-I nucleoprotein (NP)  
118 were elicited in a third of human rVSVΔG-EBOV-GP vaccine recipients [16].

119

120 Expanding our understanding of immunity elicited by the rVSVΔG-EBOV-GP vaccine against  
121 the target antigen and the VSV-I vector is critical for understanding the potential for long-term  
122 vaccine-induced protection against EBOV and the potential need for additional doses of  
123 rVSVΔG-EBOV-GP vaccine, or future doses of other rVSV-based vaccines, to successfully  
124 initiate or boost immunity to the target antigen. Although the rVSVΔG-EBOV-GP vaccine is  
125 currently approved as a single dose vaccine, the duration of protection following vaccination is

126 unclear and clinical trials assessing the immunological benefit of booster doses of rVSVΔG-  
127 EBOV-GP vaccination are underway [ClinicalTrials.gov NCT02788227, NCT02876328]. Here  
128 we describe humoral, memory B cell, and T cell responses directed against Ebola GP, VSV-I M  
129 protein, and VSV-NP elicited in the first 6 months following rVSVΔG-EBOV-GP vaccine  
130 administration from a subset of volunteers participating in an open-label, phase 2 clinical trial to  
131 assess the durability of the immune response from rVSVΔG-EBOV-GP. Additionally, we  
132 described differences in immune responses to the rVSVΔG-EBOV-GP among individuals  
133 receiving an Ebola vaccine for the first time and those who previously received different Ebola  
134 vaccines.

135

## 136 **Materials and Methods**

137 *Specimen Collection, Processing, and Storage:* Additional blood specimens for this immunology  
138 substudy were obtained from a subset of participants enrolled in the PREPARE study  
139 [ClinicalTrials.gov NCT02788227]. Study participants received the rVSVΔG-EBOV-GP vaccine  
140 at their first study visit and were randomized at 18 months to a booster dose or no booster of the  
141 rVSVΔG-EBOV-GP vaccine. Written informed consent for the PREPARE study was obtained  
142 from all participants, which permitted the study site to collect additional research specimens at  
143 scheduled study visits. The PREPARE study was approved by the US Food and Drug  
144 Administration and the Emory University Institutional Review Board.

145

146 Additional sera, plasma, and peripheral blood mononuclear cells (PBMCs) were collected at  
147 baseline, prior to rVSVΔG-EBOV-GP vaccine administration, and one month, three months, and  
148 six months after initial rVSVΔG-EBOV-GP vaccination. Serum samples were obtained using

149 serum-separating tubes containing silica clot activator and polymer gel (BD, 367983) and were  
150 processed by sitting at room temperature until clot formation was demonstrated followed by  
151 centrifugation. Plasma and PBMCs were obtained using CPT™ tubes with sodium heparin (BD  
152 #362753) following centrifugation. PBMCs were washed with phosphate-buffered saline (PBS),  
153 and cryopreserved in 90% fetal bovine serum (FBS) with 10% DMSO using a StrataCooler  
154 (Agilent) at -80°C, after which PBMCs were stored in liquid nitrogen prior to use. All samples  
155 were processed within two hours of collection. Aliquots of sera and plasma were stored at -80°C  
156 until ready for initial use and additional aliquots that underwent one freeze-thaw cycle were  
157 subsequently stored at -20°C.

158

159 *ELISA*: Antibodies to Ebola GP, VSV-I GP, VSV-I NP, and VSV-I M proteins were assessed by  
160 indirect enzyme-linked immunosorbent assay (ELISA). Vesicular stomatitis virus GP is absent  
161 from the rVSV $\Delta$ G-EBOV-GP vaccine and served as a control for natural VSV-I infection during  
162 the study period. In brief, Nunc Maxisorb plates (Fisher #439454) were coated with 1  $\mu$ g/mL of  
163 recombinant Zaire ebolavirus glycoprotein minus trans-membrane region (IBT Bioservices  
164 0501-015), VSV-I glycoprotein (Mudd-Summers strain, MyBioSource MBS1060254), VSV-I  
165 matrix protein (98COE North America strain, MyBioSource MBS1317470), or VSV-I  
166 nucleoprotein (Glasgow strain, MyBioSource MBS1026155) diluted with PBS and incubated at  
167 4°C. Plates were blocked with PBS containing 0.05% Tween-20 (PBS-T), 5% dry milk, and 4%  
168 whey for 1 hour, after which diluted serum was added in three-fold dilutions starting at 1:100  
169 and incubated at room temperature for 1 hours. Pooled serum from healthy volunteers  
170 participating an influenza vaccine study served as a negative control and serum from an Ebola  
171 convalescent patient (provided courtesy of the Centers for Disease Control and Prevention),



172 murine anti-VSV glycoprotein antibodies (Sigma-Aldrich V5507) diluted 1:2000, murine anti-  
173 VSV matrix antibodies (Kerafast EB0011) diluted 1:2000, and murine anti-VSV nucleoprotein  
174 antibodies (Kerafast EB0009) diluted 1:2000 were used as positive controls. Plates were washed  
175 with PBS-T and incubated with horseradish peroxidase (HRP) goat anti-human IgG antibody  
176 (Jackson ImmunoResearch #109-036-098) diluted 1:10000, HRP goat anti-mouse IgG Fc  
177 (ThermoFisher A16084) diluted 1:20000, or HRP goat anti-human IgM antibody (Jackson  
178 ImmunoResearch #109-035-129) diluted 1:20000 for 1 hour. KPL SureBlue™ TMB  
179 Microwell Peroxidase Substrate (KPL 52-00-00) was added for 5 minutes, the reaction was  
180 stopped with 1N hydrochloric acid (VWR #BDH3202-2), and optical densities at 450 nm were  
181 read using a Biotek EL808 ELISA plate reader at room temperature. All samples were run in  
182 duplicate. We defined a positive antibody response to VSV-I proteins by an optical density (OD)  
183 at 450 nm at 1:100 dilution at least three standard deviations above the mean OD of all  
184 individuals at baseline and for Ebola glycoprotein, by an OD at 450 nm at 1:100 dilution at least  
185 three standard deviations above the mean OD of vaccine-naïve individuals at baseline.

186

187 *PBMC Thawing:* Cryopreserved PBMCs were thawed in R10 containing DNase I (Roche  
188 #04716728001), washed, and resuspended in R10 with DNase I. Cell counting and viability  
189 assessment was performed using a Guava easyCyte counter (Luminex) per the manufacturer  
190 instructions. For intracellular cytokine staining, freshly thawed cells were rested overnight at an  
191 incubator at 37°C with 5% carbon dioxide and repeat counting and viability assessment were  
192 performed prior to use.

193

194 *IgG-producing Memory B Cell ELISpot*: IgG-producing memory B cell (MBC) ELISpots were  
195 performed using recombinant Zaire ebolavirus glycoprotein minus trans-membrane region, VSV-  
196 I matrix protein, and VSV-I nucleoprotein on PBMCs at baseline and 6 months post-vaccination.  
197 In brief, cryopreserved PBMCs were thawed, stimulated with B-poly-S containing IL-2 and  
198 R848 (Cellular Technology Limited CTL-hBPOLYS-200) and 2-mercaptoethanol (Sigma-  
199 Aldrich M3148) in a 24 well flat-bottom cell culture plate (Fisher Scientific 07-200-740), and  
200 incubated for 5 days at 37°C. 96-well multiscreen-HA plates (Millipore MSHAN4B50) were  
201 coated with 2.5 µg/mL EBOV-GP, 2 µg/mL of VSV-I M protein, VSV-I NP, or donkey anti-  
202 human IgG (Jackson Immuno Research Laboratory 709-005-149) and stored at 4°C for 1-7 days  
203 prior to use. On day 6, plates were washed with PBS-T and blocked with RPMI 1640 with L-  
204 glutamine and HEPES (Fisher MT10041CV) with 10% fetal bovine serum (Hyclone  
205 SH30088.03) and penicillin and streptomycin solution (Cellgro 30-002-CI). Three-fold dilutions  
206 of PBMCs were added to the 96-well plates starting at 1:3 dilution for viral antigen wells and  
207 1:30 dilution for anti-human IgG wells and incubated for 6 hours at 37°C. Plates were washed  
208 with PBS and PBS-T, and incubated overnight at 4°C with biotin-conjugated donkey anti-human  
209 IgG Fc antibody (Jackson Immuno Research Laboratory 709065098). After washing with PBS-  
210 T, samples were incubated with Avidin D conjugated with HRP (Vector Laboratories A-2004)  
211 for 1 hour at room temperature, plates were washed with PBS-T and PBS. 3-amino-9-  
212 ethylcarbazole substrate (Sigma A-5754) was added for 5 minutes and plates were washed with  
213 water and allowed to dry in the dark prior to being analyzed with an Immunospot S6 Universal  
214 Analyzer (Cellular Technology Limited). All samples were run in duplicate. To account for  
215 differences in the quantity of IgG-producing memory B cells present per million PBMCs, the  
216 number of antigen-specific spots per million PBMCs was divided by the total number of IgG-

217 producing spots per million PBMCs and multiplied by 100 to produce an antigen-specific/total  
218 IgG-producing memory B cell percentage. An antigen-specific/total IgG-memory B cell  
219 percentage of  $\geq 0.10\%$  was considered a positive test.

220

221 *Intracellular Cytokine Staining:* Intracellular cytokine staining of PBMCs collected at baseline  
222 and one month post-vaccination were assessed for production of interferon  $\gamma$  (IFN- $\gamma$ ), interleukin  
223 2 (IL-2), and tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) from T cells stimulated with peptide pools  
224 spanning the Zaire ebolavirus GP (Mayinga strain, JPT PM-ZEBOV-GPMay), VSV-I M protein,  
225 or VSV-I NP. Peptides sequences to match the recombinant VSV-I M (MyBioSource  
226 MBS1317470) and NP (MyBioSource MBS1026155) antigens used for ELISA and ELISpot  
227 assays were custom prepared by Genscript as 15-mer peptides with 10-mer overlaps sequence  
228 and pooled to create a concentration of 200  $\mu\text{g}/\text{mL}$ . Stimulated cells without antigen and  
229 staphylococcal enterotoxin B (Sigma-Aldrich S4881) served as negative and positive controls.

230

231 In brief, cryopreserved PBMCs were thawed and rested overnight as above. Cells were incubated  
232 with antigen-specific peptide pools, CD28 (BD #555725), and CD49d (BD #555501) for 6 hours  
233 at 37°C; brefeldin A and monensin (eBioscience #5537) were added after 2 hours of incubation.  
234 Cells were washed, stained with viability dye (Zombie Aqua, Biolegend #L423101), and  
235 fixated/permeabilized using Cytofix/Cytoperm (BD, #554722). Staining was performed using  
236 fluorescent-conjugated antibodies to CD3 (SP34-2, #562877), CD4 (L200, #560836), CD8  
237 (RPA-T8, #555367), IL-2 (MQ1-17H12, #554567), and TNF- $\alpha$  (Mab11, #560679) from BD  
238 Bioscience and IFN- $\gamma$  (4S.B3, #47731942) from eBioscience. Flow cytometry was performed on

239 a LSRII (BD Bioscience) and data analysis was performed using FlowJo. A positive antigen-  
240 specific T cell response was defined as  $\geq 0.01\%$  of T cells producing at least one cytokine and  $\geq$   
241 2-fold antigen-specific production of the same cytokine compared to the same visit negative  
242 control.

243

## 244 **Results**

245 Blood samples were obtained from thirty-two participants enrolled in the PREPARE study.  
246 Samples were obtained at baseline prior to rVSV $\Delta$ G-EBOV-GP vaccine administration, one  
247 month post-vaccination, and three months post-vaccination for all 32 participants and at six  
248 months post-vaccination for thirty-one participants. The median age of participants was 40 years  
249 (age range: 24 – 67 years) and 11/32 (34.3%) had previously received at least one heterologous  
250 investigational Ebola vaccine, either a replication-defective chimpanzee adenovirus 3 vector  
251 vaccine expressing Zaire Ebolavirus glycoprotein (ChAd3-EBO-Z) alone or ChAd3-EBO-Z  
252 followed by a modified vaccinia Ankara virus expression EBOV glycoprotein and other filovirus  
253 antigens (MVA-BN-Filo) [Table 1].

254

255 *Serology:* Ebola GP IgG antibodies met positivity criteria ( $OD \geq 0.341$  at 1:100 dilution) in 7/11  
256 (63.6%) of heterologous Ebola vaccine-experienced participants and no Ebola vaccine-naïve  
257 participants at baseline, in 31/32 (96.9%) participants one month post-vaccination, 32/32 (100%)  
258 participants three months post-vaccination, and 30/31 (96.8%) participants six months post-  
259 vaccination (Figure 1A). At baseline, the mean IgG OD to Ebola GP was significantly higher  
260 ( $p=0.03$ ) in Ebola vaccine-experienced participants compared to Ebola vaccine-naïve participants

261 (mean OD 0.847 to 0.153; Figure 1B). Ebola GP IgG ODs rose following vaccination in all but  
262 one Ebola vaccine-experienced participant who had a very high baseline Ebola GP IgG OD of  
263 3.05. Lower Ebola GP IgG OD values were observed among all participants ages 20-29  
264 compared to older participants at all time points (baseline:  $p=0.026$ , 1 month:  $p=0.003$ , 3 months:  
265  $p<0.001$ , 6 months:  $p<0.001$ ) although no differences in OD values were observed when the  
266 analysis was restricted only to participants who were vaccine-naïve at study entry (baseline:  
267  $p=0.89$ , 1 month:  $p=0.89$ , 3 months:  $p=0.95$ , 6 months:  $p=0.91$ ).

268

269 IgM antibodies to EBOV GP were positive ( $OD \geq 0.127$  at 1:100 dilution) in 18/32 (56.3%) of  
270 participants one month post-rVSV $\Delta$ G-EBOV-GP vaccination, 8/32 (25%) participants three  
271 months post-vaccination, and 6/31 (19.4%) at six months post-vaccination (Figure 1C). At  
272 baseline, no difference was observed between mean EBOV GP IgM ODs in Ebola vaccine-  
273 naïve) versus experienced participants (mean OD 0.078 vs 0.075;  $p=0.10$ , Figure 1D). Positive  
274 Ebola GP IgM ODs were observed only among Ebola vaccine-naïve participants and did not  
275 differ based on age or gender (data not shown). Among Ebola vaccine-naïve participants at  
276 enrollment, IgM responses were observed in 85.7%, 38.1%, and 28.6% at one month, three  
277 months, and six months post-vaccination, respectively.

278

279 No participants developed IgG antibodies to VSV-I M protein ( $OD \geq 2.773$  at 1:100 dilution;  
280 Figure 2A). One participant had IgM antibodies to VSV-I M protein ( $OD \geq 0.173$  at 1:100  
281 dilution) detectable up to 3 months post-vaccination and one participant had an isolated, positive  
282 IgM VSV-I M protein level at baseline (Figure 2B). One participant developed a transient IgG

283 responses to VSV-I NP ( $OD \geq 2.359$  at 1:100 dilution) at one month post-vaccination (Figure  
284 2C). Two participants developed an IgM response to VSV-I NP ( $OD \geq 0.297$  at 1:100 dilution)  
285 one month post-vaccination while one participant had positive IgM antibodies to VSV-I NP  
286 detected only at baseline (Figure 2D). No participant developed IgG responses ( $OD \geq 1.584$ ) to  
287 VSV-I GP during the study period (Figure 2E).

288

289 *IgG-Producing MBCs:* At baseline, 6 participants (19.4%), all of whom were Ebola-vaccine  
290 experienced, had detectable IgG-producing MBCs to EBOV GP while 31/31 (100%) had  
291 detectable EBOV GP antigen-specific IgG-producing MBCs at six months post-vaccination  
292 (Figure 3A; 3B). The percentage of EBOV GP specific MBCs was only weakly correlated with  
293 EBOV GP IgG ODs at 6 months post-vaccination ( $r=0.06$ ). At baseline, 2 participants (6.5%)  
294 and 4 participants (12.9%) had detectable IgG-producing MBC responses to VSV-I NP and  
295 VSV-I M protein, respectively. Among participants positive for IgG-producing memory B cells  
296 to VSV-I antigens at baseline, VSV-I specific IgG-producing MBCs were no longer detectable at  
297 six months post-vaccination in all except one participant (3.2%) who had baseline detectable  
298 IgG-producing MBC responses to VSV-I M. Post-vaccination, two participants (6.5%)  
299 developed new IgG-producing MBC responses to VSV-I NP, both of whom also developed new  
300 IgG-producing MBC responses to VSV-I M protein (Figure 3C). One participant (3.2%)  
301 developed a new IgG-producing MBC response to VSV-I M protein post-vaccination, but not to  
302 VSV-I NP. None of the three participants with new IgG-producing MBC responses to VSV-I  
303 antigens post-vaccination had detectable serum antibodies to VSV-I M protein or NP following  
304 vaccination. IgG-producing MBC responses to VSV-I proteins were of a lower magnitude (0-

305 0.20% antigen-specific/total IgG-producing MBCs) compared to the IgG-producing MBC  
306 response elicited by EBOV GP (0.11-2.68% antigen-specific/total IgG-producing MBCs).

307

308 *Intracellular Cytokine Staining:* Positive CD4+ T cell responses following stimulation of  
309 PBMCs with peptides spanning the full-length EBOV GP were observed in 15 participants  
310 (46.9%, 9 Ebola vaccine-experienced, 6 Ebola vaccine-naïve) at baseline and 100% of  
311 participants one month post-vaccination. A significant increase in the mean percentage of CD4+  
312 T cells producing IFN- $\gamma$  post-vaccination was observed among Ebola vaccine-naïve participants  
313 ( $p=0.002$ ) while Ebola vaccine-experienced participants experienced a significant increase  
314 ( $p=0.04$ ) in the mean percentage of CD4+ T cells producing IL-2 (Figure 4A). Mean percentages  
315 of CD4+ T cells producing IL-2 and TNF- $\alpha$  upon stimulation with EBOV GP peptides were not  
316 different between Ebola vaccine-naïve and vaccine-experienced individuals at baseline or post-  
317 vaccination, while Ebola vaccine-experienced participants had higher mean percentages of CD4+  
318 T cells producing IFN- $\gamma$  than Ebola vaccine-naïve participants at baseline (0.020% to 0.004%,  
319  $p=0.009$ ) and but not one month post-vaccination (0.033% to 0.018%,  $p=0.05$ ).

320

321 Nineteen participants (59.4%, 10 Ebola vaccine-experienced and 9 Ebola vaccine-naïve) had  
322 positive CD8+ T cell responses on stimulation with EBOV GP peptides at baseline while 23/32  
323 participants (71.9%) had responses at one month post-vaccination. Significant increases in the  
324 mean percentage of CD8+ T cells producing IFN- $\gamma$  ( $p=0.005$ ) and IL-2 ( $p=0.0033$ ) post-  
325 vaccination were observed among Ebola vaccine-naïve participants (Figure 4B). Ebola vaccine-  
326 experienced participants had a higher mean percentage of CD8+ T cells producing IFN- $\gamma$  to

327 EBOV GP peptides at baseline compared to vaccine-naïve participants (0.019% to 0.003%,  
328  $p=0.001$ ), otherwise no significant differences in the mean percentage of cytokine-producing  
329 CD8+ cells upon EBOV GP peptide stimulation were observed between Ebola vaccine-  
330 experienced and vaccine-naïve participants.

331  
332 Stimulation with peptides spanning the VSV-I matrix protein led to significant increases in IFN-  
333  $\gamma$ , IL-2, and TNF- $\alpha$  from both CD4+ T cells (IFN- $\gamma$ : 0.22% to 0.67%;  $p=0.003$ ; IL-2: 0.57% to  
334 2.78%,  $p<0.001$ ; TNF- $\alpha$ : 2.78% to 7.07%,  $p<0.001$ ; Figure 4C) and CD8+ T cells (IFN- $\gamma$ : 0.19%  
335 to 1.35%;  $p=0.009$ ; IL-2: 0.26% to 1.08%,  $p=0.03$ ; TNF- $\alpha$ : 0.59% to 1.37%,  $p=0.02$ ; Figure 4D).  
336 Positive CD4+ and CD8+ T cell cytokine responses to VSV-I M protein were present in 2/32  
337 (6.3%) and 6/32 (18.8%) of participants at baseline and 17/32 (53.1%) and 16/32 (50%) of  
338 participants at 6 months post-vaccination, respectively. Baseline T cell reactivity to VSV-I M  
339 protein was not associated with differences in the fold-change of Ebola GP IgG ODs at 1 month  
340 compared to baseline (Figure 5A, CD4+ T cells:  $p=0.71$ ; CD8+ T cells:  $p=0.33$ ).

341  
342 Peptides from VSV-I NP similarly produced significant increases in IFN- $\gamma$ , IL-2, and TNF- $\alpha$   
343 from CD4+ T cells (IFN- $\gamma$ : 0.21% to 1.16%;  $p=0.001$ ; IL-2: 0.55% to 4.35%,  $p<0.001$ ; TNF- $\alpha$ :  
344 2.02% to 8.01%,  $p<0.001$ ; Figure 4E) and CD8+ T cells (IFN- $\gamma$ : 0.21% to 0.57%;  $p=0.004$ ; IL-2:  
345 0.28% to 2.42%,  $p=0.01$ ; TNF- $\alpha$ : 0.66% to 4.69%,  $p=0.047$ ; Figure 4F). Positive CD4+ and  
346 CD8+ T cell cytokine responses to VSV-I NP were present in 4/32 (12.5%) and 6/32 (18.8%) of  
347 participants at baseline and 23/32 (71.9%) and 21/32 (71.9%) of participants at 6 months post-  
348 vaccination, respectively. Neither baseline CD4+ or CD8+ reactivity to VSV-I NP were



349 associated with differences in the fold-change of EBOV GP IgG ODs at 1 month compared to  
350 baseline (Figure 5B, CD4+ T cells:  $p=0.10$ ; CD8+ T cells:  $p=0.16$ ).

351  
352 Post-vaccination CD4+ T cell responses to EBOV GP peptides were primarily mono-cytokine,  
353 while CD8+ T cell responses were predominantly mono-cytokine for Ebola vaccine-naïve  
354 participants and polyfunctional for heterologous Ebola vaccine-experienced participants (Figures  
355 6A-D). Cellular responses to VSV-I Matrix protein were predominantly mono-cytokine for both  
356 CD4+ and CD8+ T cells (Figures 6E, 6F). CD4+ T cell responses to VSV-I NP were  
357 predominantly mono-cytokine while most CD8+ T cellular responses were polyfunctional  
358 (Figures 6G, 6H).

359

## 360 **Discussion**

361 Among the 32 participants in this study, all met our definition for a positive Ebola GP IgG  
362 response by three months post-rVSV $\Delta$ G-EBOV-GP vaccination, including 4 heterologous Ebola  
363 vaccine-experienced individuals who did not meet positivity criteria at baseline. To our  
364 knowledge, this is the first study to describe the use of the rVSV $\Delta$ G-EBOV-GP vaccine among  
365 prior heterologous Ebola vaccine recipients. Notably, the rVSV $\Delta$ G-EBOV-GP vaccine induced  
366 increased EBOV GP IgG ODs in the majority of vaccine-experienced recipients, raising the  
367 potential for the rVSV $\Delta$ G-EBOV-GP vaccine to be used as a booster for recipients of  
368 heterologous Ebola vaccines with waning immunity. Failure to increase Ebola IgG OD on  
369 ELISA following rVSV $\Delta$ G-EBOV-GP vaccine administration only occurred in a single  
370 heterologous Ebola vaccine-experienced individual who exhibited high baseline ODs for EBOV

371 GP IgG antibodies well above the study-defined positivity threshold. Among participants in a  
372 previous clinical trial that administered two doses of rVSVΔG-EBOV-GP vaccine twenty-eight  
373 days apart, only 12% of participants had detectable plasma rVSVΔG-EBOV-GP virus three days  
374 after the second dose of vaccination, compared to 95% after the first dose, suggesting vaccine-  
375 induced immunity inhibits the ability of the vaccine virus to replicate with subsequent doses  
376 [17]. We hypothesize the high baseline level of pre-existing EBOV GP IgG antibodies in the  
377 participant whose Ebola GP IgG OD did not increase post-rVSVΔG-EBOV-GP vaccination were  
378 responsible for neutralizing the vaccine virus prior to the establishment of successful rVSVΔG-  
379 EBOV-GP virus infection in this individual, however since the PREPARE protocol did not  
380 include early post-vaccination time points, we cannot definitively assess whether this is the case.  
381 The failure of this individual to respond to the rVSVΔG-EBOV-GP vaccine suggests further  
382 research is needed to understand the role of pre-existing EBOV GP IgG antibodies and their  
383 potential interference with the rVSVΔG-EBOV-GP vaccine to understand which populations are  
384 most likely to benefit from booster doses of rVSVΔG-EBOV-GP.

385

386 IgM antibodies to EBOV GP generated by the rVSVΔG-EBOV-GP vaccine have been  
387 demonstrated to provide up to 50% of antibody-mediated neutralization of EBOV, and therefore  
388 may contribute to early vaccine-mediated protection from disease [18]. IgM antibodies to EBOV  
389 GP were detectable only among participants who were Ebola vaccine-naïve prior to  
390 administration of the rVSVΔG-EBOV-GP vaccine. In contrast, IgM was the primary antibody  
391 type identified four weeks following two doses of rVSVΔG-EBOV-GP vaccine given twenty-  
392 eight days apart [18]. The differences in the observed results could be due to longer durations  
393 between Ebola vaccine doses among Ebola vaccine-experienced participants in this study or the

394 type of Ebola vaccine used as the priming dose. Alternatively, it is possible that heterologous  
395 Ebola vaccine-experienced participants in this study mounted transient IgM antibody responses  
396 to rVSVΔG-EBOV-GP vaccine that resolved prior to the first post-vaccination visit one month  
397 later. Among Ebola naïve participants at baseline, IgM positivity declined after the one month  
398 visit, but was still detectable in nearly one-fifth of participants at six months post-vaccination.  
399 Prolonged EBOV GP IgM positivity following rVSVΔG-EBOV-GP vaccination have been noted  
400 in other studies, therefore caution should be used when interpreting diagnostic tests for EBOV  
401 that include EBOV GP IgM antibodies among rVSVΔG-EBOV-GP vaccinees [18, 19].

402

403 While the duration of protection against EBOV conferred by the rVSVΔG-EBOV-GP vaccine  
404 remains unclear, we demonstrated that the VSVΔG-EBOV-GP vaccine generates B cell memory  
405 to EBOV GP. All participants had detectable, circulating IgG-producing memory B cells  
406 recognizing EBOV GP following vaccination. Whether this immunological memory will be  
407 sufficient to provide complete protection against EBOV disease in the setting of waning serum  
408 antibody levels over time has yet to be determined.

409

410 Vaccine vector-directed humoral immune responses to the VSV-I matrix protein and  
411 nucleoprotein were uncommon among vaccine recipients. No participants developed IgG  
412 antibodies directed at the VSV-I matrix protein, in contrast to 28% of rVSVΔG-EBOV-GP  
413 vaccinees with detectable, although transient, IgG antibodies by Poetsch et al [16], and only one  
414 participant developed transient IgG antibodies to the VSV-I nucleoprotein. Likewise, detectable  
415 IgG-producing memory B cells to VSV-I proteins were low. Taken together, our data indicate

416 that most rVSV $\Delta$ G-EBOV-GP vaccinees do not acquire humoral immunity to viral vector  
417 proteins after one dose of rVSV $\Delta$ G-EBOV-GP vaccine. Antibodies to VSV-I matrix protein  
418 induced by the rVSV $\Delta$ G-EBOV-GP vaccine have been shown to be non-neutralizing *in vitro*, but  
419 the neutralizing capacity of VSV-I nucleoprotein antibodies in humans has not been assessed to  
420 our knowledge [16]. In a non-human primate model, antibodies to whole VSV were induced by a  
421 rVSV vaccine expressing EBOV GP, but did not impair protection from a subsequently given  
422 rVSV vaccine expressing Lassa virus GP, although only three primates were challenged [15].  
423 Whether or not anti-VSV antibodies negatively impair responses to booster doses of rVSV $\Delta$ G-  
424 EBOV-GP vaccine, or future doses other replication-competent, rVSV-based vaccines, in  
425 humans remains to be determined.

426

427 Similar to previous studies, we found the rVSV $\Delta$ G-EBOV-GP vaccine can elicit CD4<sup>+</sup> and  
428 CD8<sup>+</sup> T cells to EBOV GP producing IFN- $\gamma$  and IL-2 [6]. Production of IFN- $\gamma$  and IL-2 T cell  
429 responses to EBOV GP may be associated with the development of symptoms such as  
430 arthralgias, fatigue, headache, and myalgias following rVSV $\Delta$ G-EBOV-GP vaccination [20]. In  
431 this study, the cytokine profile produced by T cells differed between Ebola vaccine-experienced  
432 and vaccine-naïve individuals. EBOV GP CD8<sup>+</sup> T cell responses to EBOV GP were more  
433 polyfunctional in nature in this study compared to those documented by Dahlke et al., especially  
434 among heterologous Ebola vaccine-experienced participants [6]. Interestingly, some of the Ebola  
435 vaccine-naïve individuals met our criteria for detectable T cell responses to EBOV GP peptides  
436 prior to vaccination, which may represent non-specific epitope cross-reactivity in the setting of  
437 seronegativity to EBOV GP. Cytokine production from CD8<sup>+</sup> T cells stimulated with EBOV GP  
438 peptide pools prior to rVSV $\Delta$ G-EBOV-GP vaccination was also observed in some participants

439 studied by Dahlke et al. [6]. Although we cannot rule out immunological interference between  
440 pre-existing T cells recognizing EBOV GP with vaccine-induced EBOV GP antibody responses,  
441 we suspect these do not cause clinically significant interference with the rVSV $\Delta$ G-EBOV-GP  
442 vaccine-induced target antigen humoral response given 100% of participants in this study met  
443 our criteria for a positive EBOV GP IgG response by 3 months post-vaccination despite 46.9%  
444 and 59.4% of participants having CD4<sup>+</sup> and CD8<sup>+</sup> T cells, respectively, capable of producing  
445 cytokines in response to EBOV GP peptide pools at baseline.

446

447 T cell responses to peptides from VSV-I proteins were uncommon at baseline among  
448 participants, but were relatively common at one month post-vaccination, particularly to the VSV-  
449 I nucleoprotein. The VSV-I nucleoprotein is the most common target for CD8<sup>+</sup> T cell responses  
450 in mice infected with VSV-I [21], although no data exists on cellular immunity in humans  
451 infected with VSV-I to our knowledge. The proportion of participants with CD8<sup>+</sup> T cell  
452 responses to VSV-I NP peptides in this study, 71.9%, is higher than that reported in a  
453 retrospective analysis of a phase I rVSV $\Delta$ G-EBOV-GP clinical trial using three different vaccine  
454 doses, in which 36% of vaccinees demonstrated CD8<sup>+</sup> T cell responses to VSV-I nucleoprotein  
455 [16]. Interestingly, we observed more polyfunctional VSV-I nucleoprotein-specific CD4<sup>+</sup> and  
456 CD8<sup>+</sup> T cells in our study than had previously been reported following vaccination, where  
457 predominantly mono-cytokine production of TNF- $\alpha$  was observed [16]. These vector-directed T  
458 cell responses potentially could negatively affect the immune response to booster doses to rVSV-  
459 based vaccines. We did not see differences in the fold-change of the Ebola GP IgG optical  
460 density at 1 month post-vaccination between the participants in this study with and without T  
461 cells responses to VSV-I proteins at baseline, however, this should be interpreted cautiously in

462 the setting of the small number of participants with baseline T cell recognition of VSV-I  
463 proteins. The main PREPARE trial itself, from which our immunology substudy is derived,  
464 provides an opportunity to assess the impact of the vector-directed immune responses elicited by  
465 the rVSV $\Delta$ G-EBOV-GP vaccine on the response to future doses, as participants are randomized  
466 to receive or not receive a booster dose of rVSV $\Delta$ G-EBOV-GP vaccine eighteen months after  
467 the original dose.

468

469 Limitations of the study include the small number of participants assessed, especially of  
470 heterologous Ebola vaccine-experienced individuals. The Ebola vaccine-experienced individuals  
471 had previously received vaccine constructs other than the rVSV $\Delta$ G-EBOV-GP vaccine,  
472 therefore, the immune responses among Ebola vaccine-experienced individuals reported in this  
473 study may not be reflective of vaccine responses provided by homologous prime and boost with  
474 the rVSV $\Delta$ G-EBOV-GP vaccine. No early time points prior to one month post-vaccination were  
475 scheduled in the parent study to assess whether pre-existing EBOV GP IgG antibodies among  
476 Ebola vaccine-experienced participants altered the course of rVSV $\Delta$ G-EBOV-GP vaccine  
477 viremia or the development of a circulating follicular helper T cell response post-vaccination,  
478 which correlates with EBOV GP antibody titers 4 weeks after vaccination [22]; important areas  
479 for future research to determine who may be most likely to benefit from rVSV $\Delta$ G-EBOV-GP  
480 vaccine booster doses. Given the lack of data on immunity to VSV-I infection in humans and the  
481 absence of meaningful cut-offs for antibody titers, we presented data in optical density format to  
482 be comparable with previously reported studies and selected our lowest ELISA dilution as the  
483 most comprehensive for analysis, although we suspect the wide distribution of IgG ODs to all

484 VSV-I proteins at baseline by ELISA indicates non-specific antigen cross-reactivity with non-  
485 VSV-I antibodies, which has previously been reported [23].

486

487 In conclusion, the rVSV $\Delta$ G-EBOV-GP vaccine frequently elicits EBOV-GP-specific IgG  
488 antibody and IgG-producing memory B cell responses, and CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses to  
489 EBOV GP in both Ebola vaccine-naïve and experienced individuals. T cell responses to VSV-I  
490 proteins are commonly elicited by rVSV $\Delta$ G-EBOV-GP, although vaccine vector-directed  
491 humoral and IgG-producing memory B cell responses are rare. Additional research is needed to  
492 understand the implications of vaccine-elicited immunity, both to the vector and to target  
493 antigens, on the immune response to booster doses of the rVSV $\Delta$ G-EBOV-GP vaccine.

494

495 **Tables**

496 Table 1: Demographics of Study Participants

	Number of Participants (%) N= 32
<b>Gender</b>	
Female	17 (53.1%)
Male	15 (46.9%)
<b>Age (years)</b>	
20-29	3 (9.4%)
30-39	13 (40.6%)
40-49	11 (34.4%)
50-69	3 (9.4%)
≥ 60	2 (6.3%)
<b>Baseline Ebola Vaccine Status</b>	
Naïve	21 (65.6%)
ChAd3-EBO-Z only	2 (6.3%)
ChAd3-EBO-Z with MVA-BN-Filo booster	9 (28.1%)

497 ChAd3-EBO-Z: replication-defective chimpanzee adenovirus 3 vector vaccine expressing Zaire  
498 ebolavirus glycoprotein. MVA-BN-Filo: modified vaccinia Ankara virus expressing Zaire  
499 ebolavirus glycoprotein and other filovirus antigens (glycoproteins from Marburg virus, Sudan  
500 virus, and Tai Forest virus).

501



502 **Figure Legends**

503 Figure 1: Antibody responses to Zaire ebolavirus glycoprotein by ELISA

504 Baseline vaccine-experienced participants are shown in grey and vaccine-naïve participants are  
505 shown in green. A: EBOV GP IgG antibody optical densities at 1:100 dilution for each  
506 participant from baseline prior to rVSVΔG-EBOV-GP vaccination and one, three, and six  
507 months post-vaccination. The positive OD threshold is indicated by a dashed line. B: EBOV GP  
508 IgG antibody optical densities at 1:100 dilution prior to rVSVΔG-EBOV-GP vaccination for  
509 Ebola vaccine-naïve and heterologous Ebola vaccine-experienced participants,  $p=0.029$ . C:  
510 EBOV GP IgM antibody optical densities at 1:100 dilution for each participant from baseline and  
511 one, three, and six months post-vaccination. The positive OD threshold is indicated by a dashed  
512 line D: EBOV GP IgM antibody optical densities at 1:100 dilution at baseline for Ebola vaccine-  
513 naïve and heterologous Ebola vaccine-experienced participants,  $p=0.1$ . ns signifies  $p\geq 0.05$ , \*  
514 signifies  $p<0.05$ .

515

516 Figure 2: Antibody responses to vesicular stomatitis virus – Indiana strain matrix protein,  
517 nucleoprotein, and glycoprotein by ELISA

518 Optical densities for each participant from baseline and one, three, and six months post-  
519 vaccination at 1:100 dilution for A) IgG antibodies to VSV-I matrix protein, B) IgM antibodies  
520 to VSV-I matrix protein, C) IgG antibodies to VSV-I nucleoprotein, D) IgM antibodies to VSV-I  
521 nucleoprotein, and E) IgG antibodies to VSV-I glycoprotein. The positive OD threshold is  
522 indicated by a dashed line and individuals with at least one value exceeding the positivity

523 threshold are shown in red. The VSV-I matrix protein and nucleoprotein are present in the  
524 rVSVΔG-EBOV-GP vaccine while the VSV-I glycoprotein is absent from the vaccine.

525

526 Figure 3: Representative IgG-producing memory B cell ELISpots at baseline and 6 months post-  
527 rVSVΔG-EBOV-GP vaccination

528 A: A representative ELISpot from an Ebola vaccine-naïve participant demonstrating a new IgG-  
529 producing memory B cell (MBC) response at six months post-vaccination to EBOV GP only. B:  
530 A representative ELISpot from a heterologous Ebola vaccine-experienced participant with IgG-  
531 producing MBC responses to EBOV GP both at baseline and six months post-rVSVΔG-EBOV-  
532 GP vaccination. C: A representative ELISpot from an Ebola vaccine-naïve participant  
533 demonstrating new IgG-producing MBC responses at six months post-vaccination to EBOV GP,  
534 VSV-I M protein, and VSV-I NP.

535

536 Figure 4: Intracellular cytokine staining for IFN- $\gamma$ , IL-2, and TNF- $\alpha$  from CD4+ and CD8+ T  
537 cells

538 Peripheral blood mononuclear cells from vaccinees at baseline and one month following  
539 rVSVΔG-EBOV-GP vaccination were assessed for production of IFN- $\gamma$ , IL-2, and TNF- $\alpha$  from  
540 CD4+ or CD8+ T cells by intracellular cytokine staining using pooled peptides spanning the  
541 entire Zaire ebolavirus glycoprotein (A, B), VSV-I matrix protein (C, D), or VSV-I  
542 nucleoprotein (E,F). ns signifies  $p \geq 0.05$ , \* signifies  $p < 0.05$ , \*\* signifies  $p < 0.001$ .

543

544 Figure 5: Fold change in Ebola IgG antibody optical densities at 1 month compared to baseline  
545 according the detectability of T cells recognizing VSV-I M (A) or NP (B) peptide pools at  
546 baseline. Median values with 95% intervals are shown.

547

548 Figure 6: Pie charts representing the functionality of CD4+ or CD8+ T cells at one month post-  
549 rVSVΔG-EBOV-GP vaccination in response to peptides from Zaire ebolavirus glycoprotein,  
550 VSV-I matrix protein, or VSV-I nucleoprotein.

551 Pie charts representing the mean functionality of CD4+ T cells (A, C, E, G) and CD8+ T cells  
552 (B, D, F, H) at one month following rVSVΔG-EBOV-GP vaccination to EBOV GP for Ebola  
553 vaccine-naïve (A, B, n=21) or Ebola vaccine-experienced (C, D, n=11) participants, and to VSV-  
554 I matrix protein (E,F, n=32) and VSV-I NP (G, H, n=32) among all participants. Due to  
555 rounding, the total mean percentage of cells of each functionality may not add up precisely to  
556 100%.

557

558 **Acknowledgements:** We also wish to acknowledge the main study team at the NIH Clinical  
559 Center and at the University of Minnesota Data Center under whose auspices the PREPARE trial  
560 has been conducted. We would also like to thank our study participants for their volunteerism  
561 and acknowledge the important contributions of the following Emory Hope Clinic staff  
562 members: Dawn Battle, Mary Bower, Justin Colwell, Rijalda Deovic, Tamera Franks, Tigisty  
563 Girmay, Mari Hart, Christopher Huerta, Hannah Huston, Sara Jo Johnson, Brandi Johnson, Dean  
564 Kleinhenz, Pam Lankford-Turner, Hollie Macenczak, Regina Mosley, Eileen Osinski, Michele  
565 McCullough, Divyanshu Raheja, Brittany Robinson, Sirajud-Deen Talib and Juton Winston.

566

567 **References:**

- 568 [1] Centers for Disease Control and Prevention. 2014-2016 Ebola Outbreak in West Africa.  
569 2019.
- 570 [2] World Health Organization. 10th Ebola outbreak in the Democratic Republic of the Congo  
571 declared over; vigilance against flare-ups and support for survivors must continue. 2020.
- 572 [3] European Medicines Agency. Ebola. 2019.
- 573 [4] Merck Sharp & Dohme Corp. ERVEBO®(Ebola Zaire Vaccine, Live) Suspension for  
574 intramuscular injection [package insert]. US Food and Drug Administration Website  
575 <https://wwwfdagov/media/133748/download> Accessed 1 July 2021.
- 576 [5] World Health Organization. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola  
577 vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic  
578 Republic of the Congo: an example of integration of research into epidemic response. 2019.
- 579 [6] Dahlke C, Kasonta R, Lunemann S, Krahlng V, Zinser ME, Biedenkopf N, et al. Dose-  
580 dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.  
581 EBioMedicine. 2017;19:107-18.
- 582 [7] Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, et al. Antibodies  
583 are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in  
584 nonhuman primates. Proc Natl Acad Sci U S A. 2013;110:1893-8.
- 585 [8] Antonello J, Grant-Klein RJ, Nichols R, Kennedy SB, Dubey S, Simon JK. Serostatus cutoff  
586 levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus - Zaire  
587 Ebola virus envelope glycoprotein vaccine: An evidence-based analysis. Vaccine. 2020;38:4885-  
588 91.

- 589 [9] Menicucci AR, Sureshchandra S, Marzi A, Feldmann H, Messaoudi I. Transcriptomic  
590 analysis reveals a previously unknown role for CD8(+) T-cells in rVSV-EBOV mediated  
591 protection. *Sci Rep.* 2017;7:919.
- 592 [10] Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy  
593 assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind,  
594 randomised, placebo-controlled, test-of-concept trial. *Lancet (London, England).* 2008;372:1881-  
595 93.
- 596 [11] Auclair S, Liu F, Niu Q, Hou W, Churchyard G, Morgan C, et al. Distinct susceptibility of  
597 HIV vaccine vector-induced CD4 T cells to HIV infection. *PLoS Pathog.* 2018;14:e1006888-e.
- 598 [12] Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, et al. Human  
599 adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1  
600 vaccine. *J Clin Invest.* 2012;122:359-67.
- 601 [13] Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5  
602 immune complexes creates an improved environment for replication of HIV in T cells. *J Exp*  
603 *Med.* 2008;205:2717-25.
- 604 [14] Roberts A, Buonocore L, Price R, Forman J, Rose JK. Attenuated vesicular stomatitis  
605 viruses as vaccine vectors. *Journal of virology.* 1999;73:3723-32.
- 606 [15] Marzi A, Feldmann F, Geisbert TW, Feldmann H, Safronetz D. Vesicular stomatitis virus-  
607 based vaccines against Lassa and Ebola viruses. *Emerg Infect Dis.* 2015;21:305-7.
- 608 [16] Poetsch JH, Dahlke C, Zinser ME, Kasonta R, Lunemann S, Rehtien A, et al. Detectable  
609 Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following  
610 VSV-Ebola Virus Vaccination in Humans. *J Infect Dis.* 2019;219:556-61.

611 [17] Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, et al. A Recombinant  
612 Vesicular Stomatitis Virus Ebola Vaccine. *N Engl J Med.* 2017;376:330-41.

613 [18] Khurana S, Fuentes S, Coyle EM, Ravichandran S, Davey RT, Jr., Beigel JH. Human  
614 antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing  
615 IgM antibodies. *Nat Med.* 2016;22:1439-47.

616 [19] Koch T, Rottstegge M, Ruibal P, Gomez-Medina S, Nelson EV, Escudero-Pérez B, et al.  
617 Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite  
618 Similar Levels of Circulating Immunoglobulins. *Viruses.* 2020;12.

619 [20] Davis C, Tipton T, Sabir S, Aitken C, Bennett S, Becker S, et al. Postexposure Prophylaxis  
620 With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the  
621 United Kingdom: An Operational, Safety, and Immunogenicity Report. *Clin Infect Dis.*  
622 2020;71:2872-9.


623 [21] Puddington L, Bevan MJ, Rose JK, Lefrancois L. N protein is the predominant antigen  
624 recognized by vesicular stomatitis virus-specific cytotoxic T cells. *J Virol.* 1986;60:708-17.

625 [22] Farooq F, Beck K, Paolino KM, Phillips R, Waters NC, Regules JA, et al. Circulating  
626 follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-  
627 ZEBOV Ebola vaccine. *Scientific reports.* 2016;6:27944-.


628 [23] Hardgrave KL, Neas BR, Scofield RH, Harley JB. Antibodies to vesicular stomatitis virus  
629 proteins in patients with systemic lupus erythematosus and in normal subjects. *Arthritis Rheum.*  
630 1993;36:962-70.

631


### A EBOV GP IgG Antibodies



### B Baseline EBOV GP IgG Antibodies



### C EBOV GP IgM Antibodies



### D Baseline EBOV GP IgM Antibodies

